Mylan Can't Duck Securities Fraud Suit, Investors Say
Investors in EpiPen maker Mylan NV have pushed back against the pharmaceutical company's bid to toss their securities fraud proposed class action, telling a New York federal court that Mylan hasn't...To view the full article, register now.
Already a subscriber? Click here to view full article